Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 11, 2006, Pages 1283-1289

  Lam, Phung K ^b   Griffith, David E ^b   Aksamit, Timothy R ^b   Ruoss, Stephen J ^b   Garay, Stuart M ^b   Daley, Charles L ^b   Catanzaro, Antonino ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NONE

Author keywords

Clarithromycin; Ethambutol; Mycobacterium avium complex; Rifampin; Risk factors

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; GAMMA INTERFERON; RIFABUTIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INTERMITTENT THERAPY; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEUS; INFECTION; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NAUSEA; PARALYSIS; PNEUMONIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

AGED; ANTITUBERCULAR AGENTS; BRONCHIECTASIS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FORCED EXPIRATORY FLOW RATES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROSPECTIVE STUDIES; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 33744908339     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200509-1531OC     Document Type: Article

References (16)

1. Horsburgh CR Jr. Nelson AM. Mycobacterium avium. In: Nelson AM, Horsburgh CR Jr, editors. Pathology of emerging infections 2. Washington, DC: ASM Press; 1998. pp. 193-216.
2. Horsburgh CR Jr, Gettings J, Alexander LN, Lennox JL. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001;33:1938-1943.
3. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002;23:643-653.
4. Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex. Clin Chest Med 2002;23:633-641.
5. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999;115:1033-1040.
6. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
7. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005;172:250-253.
8. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Interlied CB, Flexner C, Neidig J, Chaisson R, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37:1234-1243.
9. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998;178:121-126.
10. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-292.
11. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-S25.
12. Catanzaro A. Diagnosis, differentiating colonization, infection, and disease. Clin Chest Med 2002;23:599-601.
13. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002;23:553-567.
14. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-750.
15. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872.
16. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581.